Uptake of FITC-Chitosan Nanoparticles by A549 Cells
暂无分享,去创建一个
Min Huang | Eugene Khor | M. Huang | E. Khor | L. Lim | Lee-Yong Lim | Zengshuan Ma | Zengshuan Ma | Min Huang
[1] Y Wang,et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[2] J. Lippincott-Schwartz,et al. Endocytosis without clathrin coats. , 2001, Trends in cell biology.
[3] S. Zigmond,et al. Inhibition of receptor-mediated but not fluid-phase endocytosis in polymorphonuclear leukocytes , 1985, The Journal of cell biology.
[4] Sek-Man Wong,et al. The degree of deacetylation of chitosan: advocating the first derivative UV-spectrophotometry method of determination. , 1998, Talanta.
[5] R. G. Anderson,et al. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation , 1993, The Journal of cell biology.
[6] J. Paulauskis,et al. Endocytosis of ultrafine particles by A549 cells. , 2001, American journal of respiratory cell and molecular biology.
[7] J. Renau‐Piqueras,et al. Neural cell adhesion molecule is endocytosed via a clathrin‐dependent pathway , 2001, The European journal of neuroscience.
[8] M. Alonso,et al. Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .
[9] Y. Machida,et al. Biodegradation and distribution of water-soluble chitosan in mice. , 1999, Biomaterials.
[10] S. Davis,et al. Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.
[11] P. Artursson,et al. Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement , 1997, Pharmaceutical Research.
[12] P. Orlandi,et al. Filipin-dependent Inhibition of Cholera Toxin: Evidence for Toxin Internalization and Activation through Caveolae-like Domains , 1998, The Journal of cell biology.
[13] J. Schnitzer,et al. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. , 2001, Advanced drug delivery reviews.
[14] J. Couet,et al. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. , 1999, Biochemical and biophysical research communications.
[15] C. Goosen,et al. Intranasal toxicity of selected absorption enhancers. , 2001, Die Pharmazie.
[16] T. Kissel,et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[17] F. Liu,et al. Cellular Uptake Study of Biodegradable Nanoparticles in Vascular Smooth Muscle Cells , 1998, Pharmaceutical Research.
[18] Per Artursson,et al. Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells , 1996, Pharmaceutical Research.
[19] M. Amiji,et al. Synthesis of a fluorescent chitosan derivative and its application for the study of chitosan-mucin interactions , 1999 .
[20] K. Janes,et al. Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[21] S. Bo,et al. Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation. , 1991, International journal of biological macromolecules.
[22] H. Junginger,et al. Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] I. Madshus,et al. Effect of reduced endocytosis induced by hypotonic shock and potassium depletion on the infection of Hep 2 cells by picornaviruses , 1987, Journal of cellular physiology.
[24] Delie,et al. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. , 1998, Advanced drug delivery reviews.
[25] Lisbeth Illum,et al. Chitosan as a Novel Nasal Delivery System for Peptide Drugs , 1994, Pharmaceutical Research.
[26] R. Kumar,et al. Hypertonic sucrose treatment enhances second messenger accumulation in vasopressin-sensitive cells. , 1993, The American journal of physiology.
[27] H Lennernäs,et al. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.